CVS Caremark Corp. (CVS) Issues FY14 Earnings Guidance
CVS Caremark Corp. (NYSE:CVS) updated its FY14 earnings guidance on Tuesday. The company provided EPS guidance of $4.36-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.47, Analyst Ratings Network.com reports. CVS Caremark Corp. also updated its Q1 guidance to $1.03-1.06 EPS.
CVS Caremark Corp. (NYSE:CVS) opened at 66.94 on Tuesday. CVS Caremark Corp. has a 52-week low of $50.21 and a 52-week high of $71.99. The stock has a 50-day moving average of $68.70 and a 200-day moving average of $63.34. The company has a market cap of $80.596 billion and a price-to-earnings ratio of 18.65.
CVS Caremark Corp. (NYSE:CVS) last announced its earnings results on Tuesday, February 11th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.11 by $0.01. The company had revenue of $32.80 million for the quarter, compared to the consensus estimate of $32.67 million. During the same quarter in the previous year, the company posted $1.14 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Analysts expect that CVS Caremark Corp. will post $3.96 EPS for the current fiscal year.
CVS has been the subject of a number of recent research reports. Analysts at ISI Group upgraded shares of CVS Caremark Corp. from a buy rating to a strong-buy rating in a research note on Wednesday, January 22nd. They now have a $78.50 price target on the stock. On a related note, analysts at Leerink Swann initiated coverage on shares of CVS Caremark Corp. in a research note on Thursday, January 9th. They set an outperform rating and a $85.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a hold rating on shares of CVS Caremark Corp. in a research note on Friday, December 20th. They now have a $76.00 price target on the stock, up previously from $71.00. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. CVS Caremark Corp. presently has an average rating of Buy and a consensus target price of $73.80.
CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.